CD22 Redirected Autologous T Cells for ALL
0-9 years 10-17 years 18-26 years
CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
Condition: B Cell Leukemias, B Cell Lymphomas
This is a single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as “CART22” cells) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.